

CURRICULUM VITAE
Denise J. Roe, Dr.P.H.
(January 2019)

Chronology of Education

University of California, Los Angeles	1973-77	Biology	B.A.	1977
University of Colorado	1977-79	Biometrics	M.S.	1979
University of California, Los Angeles	1982-88	Biostatistics	Dr.P.H.	1988

Master's Thesis Title: Variability and Predictability of Respiratory Timing in Preterm Infants
Master's Advisor & Thesis Director: Richard H. Jones, Ph.D.

Doctoral Dissertation Title: The Design of Longitudinal Studies to Assess Population Changes
in Pulmonary Function
Doctoral Advisor & Dissertation Directors: Edward L. Korn, Ph.D. and Virginia A. Clark, Ph.D.

Major Fields: Clinical Trials, Longitudinal Studies, Statistical Consulting, Epidemiology

Chronology of Employment

June 1977 - September 1977	Data Processing Statistical Analyst, Hughes Aircraft Company, Culver City, California
September 1977 - April 1979	Statistical Consultant and Remote Terminal Operator, Department of Biometrics, University of Colorado Medical Center, Denver, Colorado
May 1979 - July 1986	Senior Statistician, Department of Biomathematics, UCLA School of Medicine, and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
August 1986 - December 1988	Research Assistant, Epidemiology and Biometry Program, Arizona Cancer Center, University of Arizona, Tucson, Arizona
January 1988 - August 1988	Acting Head of the Biostatistical Unit, Arizona Cancer Center, University of Arizona, Tucson, Arizona

December 1988 - December 1990	Research Assistant Professor, Department of Family and Community Medicine, and Research Specialist, Arizona Cancer Center, University of Arizona, Tucson, Arizona
January 1991 - June 1996	Assistant Professor, Department of Family and Community Medicine, and Research Specialist, Arizona Cancer Center, University of Arizona, Tucson, Arizona
May 1992 - December 1993	Acting Head of the Biostatistical Unit, Arizona Cancer Center, University of Arizona, Tucson, Arizona
July 1996 - June 1997	Research Assistant Professor, Department of Family and Community Medicine and Assistant Research Scientist, Arizona Cancer Center, University of Arizona, Tucson, Arizona
July 1997 – June 2000	Research Associate Professor, University of Arizona Prevention Center, University of Arizona, Tucson, Arizona
July 1997 – February 2002	Director, Biostatistical Unit, Arizona Cancer Center, University of Arizona, Tucson, Arizona
July 2000 – June 2003	Associate Professor, Division of Epidemiology and Biostatistics, Mel and Enid Zuckerman Arizona College of Public Health, University of Arizona, Tucson, Arizona
October 2001 – November 2005	Associate Dean of Academic Affairs, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
July 2003 – June 2006	Professor, Division of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
December 2005 – December 2006	Senior Associate Dean, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
July 2006 – present	Professor with tenure, Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
January 2009 – June 2017	Section Chair, Biostatistics, Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona

January 2009 – present Director, Biostatistics Shared Resource, The University of
Arizona Cancer Center, University of Arizona, Tucson,
Arizona

Honors and Awards

1978 Maurice Davies Student Award for noteworthy work in statistics (Colorado-
Wyoming chapter of the American Statistical Association)
1982 – 1983 Public Health Service Traineeship, University of California, Los Angeles
1987 – 1988 In-Candidacy Fee Offset Grant, University of California, Los Angeles
1988 Delta Omega Society Honorary Membership Based on Academic Excellence and
Demonstrated Leadership Qualities, University of California, Los Angeles
1998 Educator of the Year, Arizona Prevention Center
2005, 2015 Teaching Award, Mel and Enid Zuckerman College of Public Health

Service (2010 – Present)

Citizenship

Intramural

The University of Arizona Cancer Center

2007 – 2016 Member, Data and Safety Monitoring Board
2008 – 2015 Chair, Phase I/II Cancer Prevention Consortium Data and Safety
Monitoring Board
2010 – 2017 Reviewer, Better Than Ever Grant Applications
2010 – present Member, Scientific Review Committee
2011 – present Reviewer, American Cancer Society Institutional Research Grants
2016 Reviewer, Cancer Disparities Pilot Projects
2017 – present Reviewer, Basic/Clinical Partnership Applications

Mel and Enid Zuckerman College of Public Health/Arizona Prevention Center

2008 – 2012 Member, Promotion and Tenure Committee
2009 – 2017 Section Chair, Biostatistics
2009 – 2017 Member, Education Committee
2011 – present Member, Search Committee for Biostatistics Faculty
2014 Member, Dean Hakim's Five Year Review Committee
2015 – 2016 Chair, Epidemiology & Biostatistics Promotion and Tenure Committee

The University of Arizona

2007 – present Regular member, Graduate Interdisciplinary Program (GIDP) in Statistics
2007 – 2010 Member, Executive Committee, GIDP in Statistics
2011 – 2015 Member, Graduate Council

2014 – 2015 Member, Family and Community Medicine Department Chair Search
 Committee
2016 – present Member, University Promotion and Tenure Committee

Extramural

Professional Memberships

American Statistical Association
International Biometric Society

Funding Agency Reviews

Loan Repayment Program Special Emphasis Panel (NCI), April 2006, April 2007, April 2008, May 2009, May 2010, May 2011, April 2012, April 2013, April 2014, April 2015, April 2016

Final Performance Review, Pennsylvania Department of Health, January 2008, May 2008, October 2008, November 2010, September 2012, May 2013, November 2014, June 2015, April 2017, April 2018

Peer Review Panel for Cancer Diagnostics for Small Business and Universities,
Pennsylvania Department of Health, January 2012, Philadelphia, Pennsylvania

Florida Department of Health, December 2017, December 2018

Acute Neural Injury and Epilepsy Study Section, Ad Hoc Member, February 2014, June 2014, February 2015, June 2015, February 2016, June 2016

Acute Neural Injury and Epilepsy Study Section, Charter Member, 2016 – 2020 (October, February, June meetings)

Journal Reviews

The Journal of Laboratory and Clinical Medicine
Preventive Medicine
American Journal of Public Health
The American Statistician
Biopharmaceutics and Drug Disposition
Journal of the National Cancer Institute
Journal of Medical and Pediatric Oncology
Journal of Agricultural, Biological, and Environmental Statistics
Journal of Clinical Oncology

National Organizations

Council of Sections Representative, Biometrics Section, American Statistical Association,
January 2009 – December 2011.

Member, Presidents' Award Committee, Committee of Presidents of Statistical Societies (COPSS), January 2013 – December 2015.

Publications

Book Chapters

1. * Keeseey J, Lindstrom J, Naiem F, **Roe D**, Walford R: Immunoregulation of human acetylcholine receptor antibodies specific for myasthenia gravis. In: **Developmental Immunology: Clinical Problems and Aging**, Cooper EL and Brazier MAB, (eds), Academic Press, New York, 1982, pp 197-207. (Chapter reviewed the state of the field)
2. * Morton DL, **Roe DJ**, Cochran AJ: Melanoma in the Western United States: Experience with stage II melanoma at the UCLA Medical Center. In: **Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide**, Balch CM and Milton GW, (eds), Lippincott, Philadelphia, PA, 1985, pp 419-430. (Chapter reviewed the state of the field)
3. Jones SE, Miller TP, Connors JM, **Roe DJ**: Chemotherapy with or without adjuvant radiotherapy for stage I and II large cell lymphoma. In: **Adjuvant Therapy of Cancer V**, Salmon SE, (ed), Grune & Stratton, Orlando, FL, 1987, pp 755-761. (Chapter presented original research not reported elsewhere)
4. Alberts DS, Surwit EA, Peng Y-M, McCloskey T, Graham V, **Roe D**: Phase I and pharmacokinetic study of mitoxantrone by intraperitoneal administration. In: **Die lokoregionale Tumor-therapie: Moglichkeiten und Grezen**, Seeber S, Aigner KR and Enghofer E, (eds), Walter de Gruyter & Co., Berlin, 1988, pp 39-49. (Preliminary data from original research)
5. **Roe DJ**, Dalton WS, Mosley K, Salmon SE: Long-term follow-up on adjuvant adriamycin/ cyclophosphamide for node negative breast cancer. In: **Adjuvant Therapy of Cancer VI**, Salmon SE, (ed), W.B. Saunders Company, Philadelphia, PA, 1990, pp 190-195. (Original research not reported elsewhere)
6. Alberts DS, **Roe DJ**, Plezia PM, Kuhn JG, Davis LE: Prospective evaluation of a predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients. In: **Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development**, Valeriote FA, Corbett TH and Baker LH, (eds), Kluwer Academic Publishers, Boston, MA, 1992, pp 237-245. (Original research not reported elsewhere)
7. Earnest DL, Sampliner RE, **Roe DJ**, Van Leeuwen B, Guillen J, Reid M, Martinez ME, Marshall JR, Alberts DS: Protective role of wheat bran fiber: Data from marker trials. In: **Primary Prevention of Colorectal Cancer and Polyps: The Role of Fiber**, Shike M and Winawer S, (eds), Scien Worldwide Medical Education, New York, 1999. (Preliminary data from original research)

Refereed Journal Articles

1. * Callery C, Cochran AJ, **Roe DJ**, Rees W, Nathanson SD, Benedetti JK, Elashoff RM, Morton DL: Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. *Ann Surg* 1982 196(1):69-75. PubMed PMID#7092355. PubMed Central PMCID: PMC1352500
2. * Keeseey J, Naiem F, Lindstrom J, **Roe D**, Hermann C Jr, Walford R: Acetylcholine receptor antibody titer and HLA-B8 antigen in myasthenia gravis. *Archives of Neurology* **39**:73-77, 1982. PubMed PMID:6977352
3. * Ahn SS, Irie RF, Weisenburger TH, Jones PC, Juillard G, **Roe DJ**, Morton DL: Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: Correlation with clinical response. *Surgery* **92**:362-367, 1982. PubMed PMID:701129
4. * Storm FK, **Roe DJ**, Hildebrand-Zanki S, Worth GD, Morton DL, Kern DH: Natural thermal resistance of human tumor cells and the role of prostaglandin. *Surgery* **94**:376-383, 1983. PubMed PMID:6576490.
5. * Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. *Am J Roentgenol.* 1983 Nov;141(5):1027-33. PubMed PMID: 6605043.
6. Norman A, Cochran S, Bass D, Roe D. Effects of age, sex and diagnostic X-rays on chromosome damage. *Int J Radiat Biol Relat Stud Phys Chem Med.* 1984 Sep;46(3):317-21. PubMed PMID: 6333412.
7. * Bertelson CA, Giulano AE, Kern DH, Mann BD, **Roe DJ**, Morton DL: Breast cancers: Estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. *J Surg Res* 1984 **37**:257-263. PubMed PMID: 6482418.
8. * Gomes AS, Sinaiko AR, Tobian L, Cohn JN, Formanek G, **Roe DJ**, Amplatz K: Renal vein rennin sampling in essential hypertension using hydralazine and the tourniquet test. *Radiology* **153**:619-623, 1984. PubMed PMID: 6387785.
9. * Norman A, Bass D, **Roe D**: Screening human populations for chromosome aberrations. *Mutat Res* **143**:155-160, 1985. PubMed PMID: 4010696.
10. * Storm FK, Christenson DA, Olch AJ, Silberman AR, **Roe DJ**, Harrison WH, Elliot RS, Morton DL: Variability of heating patterns in animals by magnetic-loop induction hyperthermia. *J Surg Oncol* 1985 **29**:82-88. PubMed PMID: 4079390.
11. * Storm FK, Baker HW, Scanlon EF, Plenk HP, Meadows PM, Cohen SC, Olson CE, Thomson JW, Khandekar JD, **Roe DJ**, Nizze A, Morton DL: Magnetic-induction hyperthermia: Results of a 5-year multiinstitutional national cooperative trial in advanced cancer patients. *Cancer* 1985 **55**:2677-2687. PubMed PMID: 3888369.

12. * Cagle LA, Mirra JM, Storm FK, **Roe DJ**, Eilber FR: Histologic features relating to prognosis in synovial sarcoma. *Cancer* 1987 **59**:1810-1814. PubMed PMID:3828949.
13. * Storm FK, Scanlon EF, Baker HW, **Roe DJ**, Morton DL: Tumor stabilization after hyperthermia: An important criterion of response to thermal therapy. *J Surg Oncol* 1987 **34**:143-149. PubMed PMID: 3821122.
14. * Kimme-Smith C, Bassett LW, Gold RH, **Roe D**, Orr J: Mammographic dual screen-dual-emulsion-film combination: Visibility of simulated micro-calcifications and effect on image contrast. *Radiology* **165**:313-318, 1987. PubMed PMID:3310091.
15. Struck RF, Alberts DS, Horne K, Phillips JG, Peng Y-M, **Roe DJ**: Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, cross-over trial. *Cancer Research* **47**:2723-2726, 1987. PubMed PMID:3552204.
16. * Kimme-Smith C, Cochran ST, **Roe DJ**: Medical pattern recognition pitfalls in a clinical setting: Renal cell carcinoma survival prediction. *Med Phys* 1988 **15**:401-406. PubMed PMID: 3405145.
17. Davis LE, Alberts DS, Plezia PM, **Roe DJ**, Griswold DP: Predictive model for plasma concentration versus time profiles of investigational anticancer drugs in patients. *J Natl Cancer Inst* 1988 **80**:815-819. PubMed PMID: 3392741.
18. Garewal HS, Gerner EW, Sampliner RE, **Roe DJ**: Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus. *Cancer Research* 1988 **48**:3288-3291. PubMed PMID: 3338650.
19. * Storm FK, Elashoff RM, Baker HW, Scanlon EF, Drury B, Lee M, **Roe D**, Morton DL: Thermal dose-response of magnetic-induction thermoradiotherapy. *J Surgical Oncology* 1988 **39**:79-83. PubMed PMID:3172795.
20. Alberts DS, Surwit EA, Peng Y-M, McCloskey T, Rivest R, Graham V, McDonald L, **Roe DJ**: Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. *Cancer Res* 1988 **48**:5874-5877. PubMed PMID:3167842.
21. Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng Y-M, McCloskey TM, **Roe DJ**, Hamilton M, Salmon SE: Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. *J Clin Oncol* 1989 **7**:1733-1740. PubMed PMID:2809686.
22. Webber MM, Gomes AS, **Roe D**, LaFontaine RL, Hawkins RA: Comparison of Biello, McNeil, and PIOPED criteria for the diagnosis of pulmonary emboli on lung scans. *Am J Roentgenol.* 1990 May;**154**(5):975-81. PubMed PMID: 2108571.

23. Shamdas GJ, Garewal HS, Roe DJ. Usefulness of bone-marrow biopsy during induction therapy for acute myeloid leukemia. *Lancet*. 1992 Jan 18;339(8786):178. PubMed PMID: 1346026.
24. Scuderi P, Finley PR, Shon BY, Udall JN, **Roe DJ**, Chong AS-F: Regulation of tumor necrosis factor secretion in leukocytes from alpha-1-antitrypsin deficient humans. *Immunol Invest*. 1990 Oct-Dec;19(5-6):453-61. PubMed PMID: 1705919.
25. Plezia PM, Alberts DS, Kessler JF, Berens PL, Chase JL, **Roe DJ**: Randomized crossover comparison of high-dose intravenous metoclopramide versus a five drug antiemetic regimen. *J Pain Symptom Manage*. 1990 Apr;5(2):101-8. PubMed PMID: 2189929.
26. Lehnert M, Dalton WS, **Roe D**, Emerson S, Salmon SE: Synergistic inhibition by verapamil and quinine of p-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. *Blood*. 1991 Jan 15;77(2):348-54. PubMed PMID: 1670760.
27. Alberts DS, Mason-Liddil N, Plezia PM, **Roe DJ**, Dorr RT, Struck RF, Phillips JG: Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: A placebo-controlled clinical trial. *J Natl Cancer Inst*. 1991 Dec 4;83(23):1739-42. PubMed PMID: 1770553.
28. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, **Roe DJ**, Miller TP: Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. *Blood*. 1991 Jul 1;78(1):44-50. PubMed PMID: 1676918.
29. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, **Roe DJ**, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line *Br J Cancer*. 1991 Jun;63(6):923-9. PubMed PMID: 1676902 .PubMed Central PMCID: PMC1972545
30. Taylor CW, Alberts DS, Peng Y-M, McCloskey TM, Matzner M, **Roe DJ**, Plezia PM, Grindey GB, Hamilton M, Seitz D: Antitumor activity and clinical pharmacology of sulofenur in patients with advanced ovarian cancer. *J Natl Cancer Inst*. 1992 Dec 2;84(23):1798-802. PMID#1433369
31. **Roe DJ**, Korn EL: Time-period effects in longitudinal studies measuring average rates of change. *Stat Med*. 1993 May 15;12(9):893-900. PubMed PMID: 8392217.
32. Alberts DS, Einspahr J, Aickin M, Hixson L, Earnest D, Roe D, Powell M. Validation of proliferation indices as surrogate endpoint biomarkers. *J Cell Biochem Suppl*. 1994; 19:76-83. PMID: 7823609
33. Peng Y-M, Peng Y-S, Lin Y, Moon T, **Roe DJ**, Ritenbaugh C: Concentrations and plasma-tissue-diet relationships of carotenoids, retinoids and tocopherols in humans. *Nutr Cancer*. 1995;23(3):233-46. PubMed PMID: 7603884.

34. Einspahr J, Alberts D, Xie T, Ritchie J, Earnest D, Hixson L, Powell M, **Roe D**, Grogan T: Comparison of proliferating cell nuclear antigen (PCNA) versus the more standard measures of rectal mucosal proliferation rates in subjects with a history of colorectal cancer and normal age-matched controls. *Cancer Epidemiol Biomarkers Prev.* 1995 Jun;4(4):359-66. PubMed PMID: 7655331.
35. **Roe DJ**, Alberts DS, Wargovich MJ, Bostick RM, Garewal HS, Einspahr J, Fosdick L, Ramsey L, Woods C, McGee DL: Reproducibility of the measurement of colonic proliferation using bromodeoxyuridine across laboratories *Cancer Epidemiol Biomarkers Prev.* 1996 May;5(5):349-53. PubMed PMID: 9162300.
36. **Roe DJ**, Harford AM, Zager PG, Wiltbank TB, Kirilin L, Della-Valle AM, Van Wyck DB: Iron utilization after iron dextran for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents. *Am J Kidney Dis.* 1996 Dec;28(6):855-60. PubMed PMID: 8957037.
37. Tricot G, Alberts DS, Johnson C, **Roe DJ**, Dorr RT, Vesole DH, Jagannath S, Meyers R, Barlogie B: Safety of autotransplants with high dose melphalan in renal failure: A pharmacokinetic and toxicity study. *Clin Cancer Res.* 1996 Jun;2(6):947-52. PubMed PMID: 9816255.
38. List AF, Spier CS, Grogan TM, Johnson C, **Roe DJ**, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WD: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. *Blood.* 1996 Mar 15;87(6):2464-9. PubMed PMID: 8630412.
39. **Roe DJ**: Comparison of population pharmacokinetic modeling using simulated data: results from the Population Modeling Work Group. *Stat Med.* 1997 Jun 15;16(11):1241-57; discussion 1257-62. PubMed PMID: 9194270.
40. **Roe DJ**, Karol MD: Averaging pharmacokinetic parameter estimates from experimental studies: Statistical theory and application. *J Pharm Sci.* 1997 May;86(5):621-4. PubMed PMID: 9145389..
41. Kling PJ, Sullivan TM, Leftwich ME, **Roe DJ**: Score for neonatal acute physiology and phlebotomy loss predict erythrocyte transfusions in premature infants. *Arch Pediatr Adolesc Med.* 1997 Jan;151(1):27-31. PubMed PMID: 9006525.
42. Valenzuela TD, **Roe DJ**, Cretin S, Spaite DW, Larsen MP: Estimating effectiveness of cardiac arrest interventions: A logistic regression survival model. *Circulation.* 1997 Nov 18;96(10):3308-13. PubMed PMID: 9396421.
43. Chow H-H, Tolle KM, **Roe DJ**, Elsberry V, Chen H: Application of neural networks to population pharmacokinetic data analysis. *Pharm Sci.* 1997 Jul;86(7):840-5. PubMed PMID: 9232526.

44. Walter FG, Gibly RL, Knopp RK, **Roe DJ**: Squamous cells as predictors of bacterial contamination in urine samples. *Ann Emerg Med*. 1998 Apr;31(4):455-8. PubMed PMID: 9546013.
45. Peng Y-M, Peng Y-S, Childers JM, Hatch KD, **Roe DJ**, Lin Y, Lin P: Concentrations of carotenoids, tocopherols and retinol in paired plasma and cervical tissue of patients with cervical cancer, precancer, and noncancerous diseases. *Cancer Epidemiol Biomarkers Prev*. 1998 Apr;7(4):347-50. PubMed PMID: 9568792.
46. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, **Roe D**, Payne CM, Nelson MA: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. *Cancer Lett*. 1998 Mar 13;125(1-2):103-10. PubMed PMID: 9566703.
47. Bernstein C, Bernstein H, Garewal H, Dinning P, Jabi R, Sampliner RE, McCuskey MK, Panda M, **Roe DJ**, L'Heureux L, Payne C: A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. *Cancer Res*. 1999 May 15;59(10):2353-7. PubMed PMID: 10344743.
48. Martinez ME, Heddens D, Earnest DL, Bogert CL, **Roe D**, Einspahr J, Marshall JR, Alberts DS: Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. *J Natl Cancer Inst*. 1999 Jun 2;91(11):950-3. PubMed PMID: 10359547.
49. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, **Roe D**, Bhujwala ZM, Gillies RJ: Enhancement of chemotherapy by manipulation of tumour pH. *Br J Cancer*. 1999 Jun;80(7):1005-11. PubMed PMID: 10362108; PubMed Central PMCID: PMC2363059.
50. Risendal B, **Roe D**, DeZapien J, Papenfuss M, Giuliano A: Influence of health care, cost, and culture on breast cancer screening: issues facing urban American Indian women. *Prev Med*. 1999 Dec;29(6 Pt 1):501-9. PubMed PMID: 10600431.
51. Taetle R, Aickin M, Panda L, Emerson J, **Roe D**, Thompson F, Davis J, Trent J, Alberts D: Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. *Genes Chromosomes Cancer*. 1999 May;25(1):46-52. PubMed PMID: 10221339.
52. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, **Roe D**, Adair L, Thompson F, Liu Y, Wisner L, Davis JR, Trent J, Alberts DS: Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. *Genes Chromosomes Cancer*. 1999 Jul;25(3):290-300. PubMed PMID: 10379876.
53. Earnest DL, Sampliner RE, **Roe DJ**, van Leeuwen B, Guillen J, Reid M, Martinez ME, Marshall JR, Alberts DS: Progress report: the Arizona phase III study of the effect of wheat bran fiber on recurrence of adenomatous colon polyps. *Am J Med*. 1999 Jan 25;106(1A):43S-45S. PubMed PMID: 10089115.

54. Alberts DS, Martinez ME, **Roe DJ**, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, Reid ME, Ritenbaugh C, Vargas PA, Bhattacharyya AB, Earnest DL, Sampliner RE: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. *N Engl J Med*. 2000 Apr 20;342(16):1156-62. PubMed PMID: 10770980.
55. Chow S, Earnest D, Clark D, Mason-Liddil N, Kramer C, Einsphar J, Guillen-Rodriguez J, **Roe D**, Malone W, Crowell J, Alberts D: Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. *Cancer Epidemiol Biomarkers Prev*. 2000 Apr; 9(4):351-6. PubMed PMID: 10794478.
56. Crowley CL, Payne CM, Bernstein H, Bernstein C, **Roe D**: The NAD+ precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate. *Cell Death Differ*. 2000 Mar;7(3):314-26. PubMed PMID: 10745276.
57. Nelson MA, Radmacher MD, Simon R, Aickin M, Yang J-M, Panda L, Emerson J, **Roe D**, Adair L, Thompson F, Bangert J, Leong SP, Taetle R, Salmon S, Trent J: Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. *Cancer Genet Cytogenet*. 2000 Oct 15;122(2):101-9. PubMed PMID: 11106819.
58. Baines AT, Holubec H, Basye JL, Thorne P, Bhattacharyya AK, Apallholz J, Shriver B, Cui H, **Roe D**, Clark LC, Earnest DL, Nelson MA: The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts. *Cancer Lett*. 2000 Nov 28;160(2):193-8. PubMed PMID: 11053649.
59. Hill AL, **Roe DJ**, Taren DL, Muramoto MM, Leischow SJ: Efficacy of transdermal nicotine in reducing post-cessation weight gain in a Hispanic sample. *Nicotine Tob Res*. 2000 Aug;2(3):247-53. PubMed PMID: 11082825
60. Valenzuela TD, **Roe DJ**, Graham N, Clark LL, Spaite DW, Hardman RG: Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. *N Engl J Med*. 2000 Oct 26;343(17):1206-9. PubMed PMID: 11071670.
61. Calaluce R, Earnest DL, Heddens D, Einspahr JG, **Roe D**, Bogert CL, Marshall JR, Alberts DS: Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. *Cancer Epidemiol Biomarkers Prev*. 2000 Dec;9(12):1287-92. PubMed PMID: 11142413.
62. Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, Peng YM, Goldman R, Foote JA, Warneke JA, Salasche S, **Roe DJ**, Bowden GT: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. *Cancer Epidemiol Biomarkers Prev*. 2000 Dec;9(12):1281-6. PubMed PMID: 11142412

63. Foote JA, Harris RB, Giuliano AR, **Roe DJ**, Moon TE, Cartmel B, Alberts DS: Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. *Int J Cancer*. 2001 Jan 20;95(1):7-11. PubMed PMID: 11241303; PubMed Central PMCID: PMC2637530.
64. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, **Roe D**, List AF: Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. *J Clin Oncol*. 2001 Mar 15;19(6):1589-99. Erratum in: *J Clin Oncol* 2001 May 1;19(9):2583. PubMed PMID: 11250987
65. Sedjo RL, Inserra P, Abrahamsen M, Harris RB, **Roe DJ**, Baldwin S, Giuliano AR: Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. *Cancer Epidemiol Biomarkers Prev*. 2002 Apr;11(4):353-9. PubMed PMID: 11927495.
66. Bernstein H, Holubec H, Warneke JA, Garewal H, Earnest DL, Payne CM, **Roe DJ**, Cui H, Jacobson EL, Bernstein C: Patchy field defects of apoptosis resistance and dedifferentiation in flat mucosa of colon resections from colon cancer patients. *Ann Surg Oncol*. 2002 Jun;9(5):505-17. PubMed PMID: 12052764.
67. Giuliano AR, Harris R, Sedjo RL, Baldwin S, **Roe D**, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, Hatch K: Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. *J Infect Dis*. 2002 Aug 15;186(4):462-9. Epub 2002 Aug 2. PubMed PMID: 12195372.
68. Heddens D, Alberts DS, Hannigan EV, Williams SD, Garcia D, **Roe DJ**, Bell J, Alvarez RD: Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. *Gynecol Oncol*. 2002 Sep;86(3):239-43. PubMed PMID: 12217742
69. Jacobs ET, Giuliano AR, **Roe DJ**, Guillen-Rodriguez JM, Hess LM, Alberts DS, Martinez ME: Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the Wheat Bran Fiber Trial. *Cancer Epidemiol Biomarkers Prev*. 2002 Sep;11(9):906-14. Erratum in: *Cancer Epidemiol Biomarkers Prev*. 2002 Dec;11(12):1699.. PubMed PMID: 12223437
70. Jacobs ET, Giuliano AR, **Roe DJ**, Guillen-Rodriguez JM, Alberts DS, Martinez ME: Baseline dietary fiber intake and colorectal adenoma recurrence in the Wheat Bran Fiber randomized trial. *J Natl Cancer Inst*. 2002 Nov 6;94(21):1620-5. PubMed PMID: 12419788.
71. Sedjo RL, **Roe DJ**, Abrahamsen M, Harris RB, Craft N, Baldwin S, Giuliano AR: Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection. *Cancer Epidemiol Biomarkers Prev*. 2002 Sep; 11(9):876-84. PubMed PMID: 12223432.

72. Giuliano AR, Sedjo RL, **Roe DJ**, Harris R, Baldwin S, Papenfuss MR, Abrahamsen M, Inserra P: Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). *Cancer Causes Control*. 2002 Nov;13(9):839-46. PubMed PMID: 12462549.
73. Giuliano AR, Siegel EM, **Roe DJ**, Ferreira S, Baggio ML, Galan L, Duarte-Franco E, Villa LL, Rohan TE, Marshall JR, Franco E: Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History Study. *J Infect Dis*. 2003 Nov 15;188(10):1508-16. Epub 2003 Nov 3. PubMed PMID: 14624376
74. Alberts DS, Einspahr JG, Earnest DL, Krutzsch MF, Lin P, Hess LM, Heddens DK, **Roe DJ**, Martinez ME, Salen G, Batta AK: Fecal bile acid concentrations in a subpopulation of the wheat bran fiber colon polyp trial. *Cancer Epidemiol Biomarkers Prev*. 2003 Mar;12(3):197-200. PubMed PMID: 12646507.
75. Reid ME, Marshall JR, **Roe D**, Lebowitz M, Alberts D, Battacharyya AK, Martinez ME: Smoking exposure as a risk factor for prevalent and recurrent colorectal adenomas. *Cancer Epidemiol Biomarkers Prev*. 2003 Oct;12(10):1006-11. PubMed PMID: 14578135.
76. Nichol G, Valenzuela T, **Roe D**, Clark L, Hustzi E, Wells GA: Cost-effectiveness of defibrillation by targeted responders in public settings. *Circulation*. 2003 Aug 12;108(6):697-703. Epub 2003 Aug 4. Erratum in: *Circulation*. 2004 Jun 29;109(25):3256. PubMed PMID: 12900345.
77. Jacobs ET, Giuliano AR, **Roe DJ**, Guillen-Rodriguez JM, Hartz VL, Whitacre RC, Alberts DS, Martinez ME: Dietary change in an intervention trial of wheat bran fiber and colorectal adenoma recurrence. *Ann Epidemiol*. 2004 Apr;14(4):280-6. PubMed PMID: 15066608.
78. Frank DH, **Roe DJ**, Chow HH, Guillen JM, Choquette K, Gracie D, Francis J, Fish A, Alberts DS: Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. *Cancer Epidemiol Biomarkers Prev*. 2004 Feb;13(2):299-303. PubMed PMID: 14973093.
79. Siegel EM, Craft NE, **Roe DJ**, Duarte-Franco E, Villa LL, Franco EL, Giuliano AR: Temporal variation and identification of factors associated with endogenous retinoic acid isomers in serum from Brazilian women. *Cancer Epidemiol Biomarkers Prev*. 2004 Nov;13(11 Pt 1):1693-703. PubMed PMID: 15533895
80. Chen Z, Stini WA, Marshall JR, Martinez ME, Guillen-Rodriguez JM, **Roe D**, Alberts DS: Wheat bran fiber supplementation and bone loss among older people. *Nutrition*. 2004 Sep;20(9):747-51. PubMed PMID: 15325680
81. List A, Kurtin S, **Roe DJ**, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. *N Engl J Med*. 2005 Feb 10;352(6):549-57. PubMed PMID: 15703420

82. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, **Roe D**, Lance P, and the Phoenix and Tucson Gastroenterologist Networks: Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. *J Natl Cancer Inst.* 2005 Jun 1;97(11):846-53. PubMed PMID: 15928305.
83. Baker AF, Dragovich T, Tate WR, Ramanathan RK, **Roe D**, Hsu CH, Kirkpatrick DL, Powis G: The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. *J Lab Clin Med.* 2006 Feb;147(2):83-90. PubMed PMID: 16459166; PubMed Central PMCID: PMC1432091.
84. Walter FG, Chase PB, Fernandez MC, Cameron D, **Roe DJ**, Wolfson M: Pyridoxine does not prevent hyperbaric oxygen-induced seizures in rats. *J Emerg Med.* 2006 Aug;31(2):135-8. PubMed PMID: 17044573.
85. Clouser MC, Harris RB, **Roe DJ**, Saboda K, Ranger-Moore J, Duckett L, Alberts DS: Risk group, skin lesion history, and sun sensitivity reliability in squamous cell skin cancer progression. *Cancer Epidemiol Biomarkers Prev.* 2006 Nov;15(11):2292-7. PubMed PMID: 17119060
86. Venker CC, Goodwin JL, **Roe DJ**, Kaemingk KL, Mulvaney S, Quan SF: Normative psychomotor vigilance task performance in children ages 6 to 11--the Tucson Children's Assessment of Sleep Apnea (TuCASA). *Sleep Breath.* 2007 Dec;11(4):217-24. PubMed PMID: 17333098.
87. Foote JA, Ranger-Moore JR, Einspahr JG, Saboda K, Kenyon J, Warneke J, Miller RC, Goldman R, Xu MJ, **Roe DJ**, Alberts DS: Chemoprevention of human actinic keratoses by topical DL-alpha cocopherol. *Cancer Prev Res (Phila).* 2009 Apr;2(4):394-400. doi: 10.1158/1940-6207.CAPR-08-0210. Epub 2009 Mar 31. PubMed PMID: 19336724; PubMed Central PMCID: PMC4154592.
88. Robey IF, Baggett BK, Kirkpatrick ND, **Roe DJ**, Dosesco J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ: Bicarbonate increases tumor pH and inhibits spontaneous metastases. *Cancer Research* **69**(6):2260-8, 2009. PubMed Central PMCID: PMC2834485
89. Clouser MC, **Roe DJ**, Foote JA, Harris RB: Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. *Pharmacoepidemiol Drug Saf.* 2009 Apr;18(4):276-83. doi: 10.1002/pds.1718. PubMed PMID: 19226541
90. Wertheim BC, Martinez ME, Ashbeck EL, **Roe DJ**, Jacobs ET, Alberts DS, Thompson PA: Physical activity as a determinant of fecal bile acid levels. *Cancer Epidemiology, Biomarkers & Prevention* **18**(5):1591-8, 2009. PubMed Central PMCID: PMC2743306

91. Chisolm-Burns MA, Spivey CA, Rehfeld R, Zawaideh M, **Roe DJ**, Gruessner R: Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. *Am J Transplant*. 2009 Nov;9(11):2497-504. doi: 10.1111/j.1600-6143.2009.02793.x. Epub 2009 Aug 14. PubMed PMID: 19681814
92. Thompson PA, Wertheim BC, **Roe DJ**, Ashbeck EL, Jacobs ET, Lance P, Martinez ME, Alberts DS: Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. *Cancer Prev Res (Phila)*. 2009 Dec;2(12):1023-30. doi: 10.1158/1940-6207.CAPR-09-0234. Epub 2009 Dec 1. PubMed PMID: 19952360; PubMed Central PMCID: PMC4120755.
93. Chambers SK, Clouser MC, Baker AF, **Roe DJ**, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS: Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. *Clin Cancer Res*. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974. PubMed PMID: 21041183; PubMed Central PMCID: PMC3074583.
94. Clouser MC, **Roe DJ**, Foote JA, Harris RB, Alberts DS: Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. *Nutr Cancer*. 2010;62(8):1058-66. doi: 10.1080/01635581.2010.492089. PubMed PMID: 21058193; PubMed Central PMCID: PMC4104190
95. Liu L-C, Lang JE, Lu Y, **Roe D**, Hwang SE, Ewing CA, Esserman LJ, Morita E, Treseler P, Leong SP: Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: A meta-analysis and single-institution experience. *Cancer*. 2011 Jan 15;117(2):250-8. doi: 10.1002/cncr.25606. Epub 2010 Sep 3. PubMed PMID: 20818649.
96. Qi W, Cooke LS, Liu X, Rimsza L, **Roe DJ**, Manziolli A, Persky DO, Miller TP, Mahadevan D: Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. *Biochem Pharmacol*. 2011 Apr 1;81(7):881-90. doi: 10.1016/j.bcp.2011.01.017. Epub 2011 Feb 1. PubMed PMID: 21291867; PubMed Central PMCID: PMC3792566.
97. Staten LK, Cutshaw CA, Davidson C, Reinschmidt K, Stewart R, **Roe DJ**: Effectiveness of the Pasos Adelante chronic disease prevention and control program in a US-Mexico border community, 2005-2008. *Prev Chronic Dis*. 2012;9:E08. Epub 2011 Dec 15. PubMed PMID: 22172175; PubMed Central PMCID: PMC3277389.
98. Cutshaw CA, Staten LK, Reinschmidt KM, Davidson C, **Roe DJ**: Depressive symptoms and health-related quality of life among participants in the Pasos Adelante chronic disease prevention and control program, Arizona, 2005-2008. *Prev Chronic Dis*. 2012;9:E24. Epub 2011 Dec 15. PubMed PMID: 22172191; PubMed Central PMCID: PMC3277398.

99. Beamer PL, Elish CA, **Roe DJ**, Loh MM, Layton DW: Differences in metal concentration by particle size in house dust and soil. *J Environ Monit.* 2012 Mar;14(3):839-44. doi: 10.1039/c2em10740f. Epub 2012 Jan 16. PubMed PMID: 22245917; PubMed Central PMCID: PMC3622451.
100. Baker AF, **Roe DJ**, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK: Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer. *Invest New Drugs.* 2013 Feb;31(1):160-6. doi: 10.1007/s10637-012-9827-5. Epub 2012 May 13. PubMed PMID: 22580577; PubMed Central PMCID: PMC3988024
101. Larkey LK, Herman PM, **Roe DJ**, Garcia F, Lopez AM, Gonzalez J, Perera PN, Saboda K. A cancer screening intervention for underserved Latina women by lay educators. *J Womens Health (Larchmt).* 2012 May;21(5):557-66. doi: 10.1089/jwh.2011.3087. Epub 2012 Mar 14. PubMed PMID: 22416791
102. Nelson-Moseke AC, Jeter JM, Cui H, **Roe DJ**, Chambers SK, Laukaitis CM. An unusual BRCA mutation distribution in a high risk cancer genetics clinic. *Fam Cancer.* 2013 Mar;12(1):83-7. doi: 10.1007/s10689-012-9581-z. PubMed PMID: 23179792; PubMed Central PMCID: PMC3563940.
103. Thompson P, **Roe DJ**, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P. Design and baseline characteristics of participants in a Phase III randomized trial of Celecoxib and Selenium for colorectal adenoma prevention. *Cancer Prev Res (Phila).* 2012 Dec;5(12):1381-93. doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11. PubMed PMID: 23060037; PubMed Central PMCID: PMC3518663.
104. Bartley AN, Parikh N, Hsu C-H, **Roe D**, Buckmeier JA, Corley L, Gallick G, Lance P, Thompson PA, Hamilton SR. Colorectal adenoma stem-like cell populations: Associations with adenoma characteristics and metachronous colorectal neoplasia. *Cancer Prev Res (Phila).* 2013 Nov;6(11):1162-70. doi: 10.1158/1940-6207.CAPR-13-0113. Epub 2013 Sep 5. PMID:24008128 PubMed Central PMCID: PMC407927
105. Hassounah NB, Nagle R, Saboda K, **Roe DJ**, Dalkin BL, McDermott KM. Primary cilia are lost in preinvasive and invasive prostate cancer. *PLoS One.* 2013 Jul 2;8(7):e68521.doi:10.1371/journal.pone.0068521.Print2013.PMID:23844214. PubMed Central PMCID: PMC 3699526.
106. Poplin GS, **Roe DJ**, Peat W, Harris RB, Burgess JL. The association of aerobic fitness with injuries in the fire service. *Am J Epidemiol.* 2014 Jan 15;179(2):149-55. doi: 10.1093/aje/kwt213. Epub 2013 Oct 31. PubMed PMID: 24186973.

107. Hongu N, Orr BJ, **Roe DJ**, Reed RG, Going SB. Global positioning system watches for estimating energy expenditure. *J Strength Cond Res.* 2013 Nov;27(11):3216-20. doi: 10.1519/JSC.0b013e31828bae0f. PubMed PMID: 23439338.
108. Phipps-Yonas H, Cui H, Sebastiao N, Brunhoeber PS, Haddock E, Deymier MJ, Klapper W, Lybarger L, **Roe DJ**, Hastings KT. Low GILT expression is associated with poor patient survival in diffuse large B-cell lymphoma. *Front Immunol.* 2013 Dec 4;4:425. doi: 10.3389/fimmu.2013.00425. eCollection 2013. PubMed PMID: 24409177; PubMed Central PMCID: PMC3885809
109. Smith LL, Larkey LK, **Roe DJ**, Buch-Gonzalez JA, Saboda K, Ainsworth BE. Self-reported physical activity patterns among low-income Latina women in Arizona. *Womens Health Issues.* 2014 May-Jun;24(3):e353-61. doi: 10.1016/j.whi.2014.02.009. PubMed PMID: 24794546.
110. Hongu N, Going SB, Orr BJ, Merchant NC, Hingle M, **Roe DJ**, Greenblatt YV, Houtkooper LB. TECH SAVVY: Mobile technologies for promoting health and physical activity. *ACMS Health & Fitness* 2014 July/August;18(4):8-15. Doi:10.1249/FIT.0000000000000050.
111. Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, **Roe DJ**, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsaz LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase II study of imexon, a pro-oxidant molecule, in relapsed and refractory B-Cell non-Hodgkin lymphoma. *Blood.* 2014 Aug 21;124(8):1259-65. doi: 10.1182/blood-2014-04-570044. Epub 2014 Jul 11. PubMed PMID: 25016003; PubMed Central PMCID: PMC4141515
112. Molmenti CL, Hibler EA, Ashbeck EL, Thomson CA, Garcia DO, **Roe D**, Harris RB, Lance P, Cisneroz M, Martinez ME, Thompson PA, Jacobs ET. Sedentary behavior is associated with colorectal adenoma recurrence in men. *Cancer Causes Control.* 2014 Oct;25(10):1387-95. doi: 10.1007/s10552-014-0444-9. Epub 2014 Jul 25. PubMed PMID: 25060482; PubMed Central PMCID: PMC4228938.
113. Larkey LK, **Roe DJ**, Weihs KL, Jahnke R, Lopez AM, Rogers CE, Oh B, Guillen-Rodriguez J. Randomized controlled trial of Qigong/Tai Chi easy on cancer-related fatigue in breast cancer survivors. *Ann Behav Med.* 2015 Apr;49(2):165-76. doi: 10.1007/s12160-014-9645-4. PubMed PMID: 25124456; PubMed Central PMCID: PMC4329282
114. Whitlow PG, Saboda K, **Roe DJ**, Bazzell S, Wilson C. Topical analgesia treats pain and decreases propofol use during lumbar punctures in a randomized pediatric leukemia trial. *Pediatr Blood Cancer.* 2015 Jan;62(1):85-90. doi: 10.1002/pbc.25236. Epub 2014 Sep 27. PubMed PMID: 25264024.

115. Bea JW, Jurutka PJ, Hibler EA, Lance P, Martinez ME, **Roe DJ**, Sardo Molmenti CL, Thompson PA, Jacobs ET. Concentrations of the vitamin D metabolite 1,25(OH)₂D and odds of metabolic syndrome and its components. *Metabolism*. 2015 Mar;64(3):447-59. doi: 10.1016/j.metabol.2014.11.010. Epub 2014 Nov 29. PubMed PMID: 25496802; PubMed Central PMCID: PMC4312532
116. Hongu N, Pop BT, Bilgic P, Orr BJ, Suzuki A, Kim AS, Merchant NC, **Roe DJ**. Usability of a smartphone food picture app for assisting 24-hour dietary recall: a pilot study. *Nutr Res Pract*. 2015 Apr;9(2):207-12. doi: 10.4162/nrp.2015.9.2.207. Epub 2014 Dec 12. PubMed PMID: 25861429; PubMed Central PMCID: PMC4388954
117. Larkey LK, McClain D, **Roe DJ**, Hector RD, Lopez AM, Sillanpaa B, Gonzalez J, Randomized controlled trial of storytelling compared to a personal risk tool intervention on colorectal cancer screening in low-income patients. *Am J Health Promot*. 2015 Nov-Dec;30(2):e59-70. doi: 10.4278/ajhp.131111-QUAN-572. Epub 2015 Jan 23. PubMed PMID: 25615708.
118. Robey IF, Lopez AM, **Roe DJ**. Safety and tolerability of long-term sodium bicarbonate consumption in cancer care. *J Integr Oncol* 2015 4: 128. doi:10.4172/2329-6771.1000128
119. Poplin GS, **Roe DJ**, Bugess JL, Peate WF, Harris RB. Fire fit: assessing comprehensive fitness and injury risk in the fire service. *Int Arch Occup Environ Health*. 2015. Jul 1 [Epub ahead of print] PubMed PMID: 26126735.
120. Hibler EA, Klimentidis, YC, Jurutka PW, Kohler LN, Lance P, **Roe DJ**, Thompson PA, Jacobs ET. CYP24A1 CYP27B1 Polymorphisms, concentrations of vitamin D, and odds of colorectal adenoma recurrence. *Nutr Cancer*. 2015;67(7):1131-41. doi: 10.1080/01635581.2015.1068818. Epub 2015 Aug 4. PubMed PMID: 26241700. PubMed Central PMCID: 4589517.
121. Baker AF, Malm SW, Pandey R, Laughren C, Cui H, **Roe D**, Chambers SK. Evaluation of hypoxia regulated gene panel in ovarian cancer. *Cancer Microenviron*. 2015 Apr;8(1):45-56. doi: 10.1007/s12307-015-0166-x. Epub 2015 May 22. PubMed PMID: 25998313; PubMed Central PMCID: PMC4449346
122. Stephen RM, Jha AK, **Roe DJ**, Truard TP, Galons JP, Kupinski MA, Frey G, Cui H, Squire S, Pagel MD, Rodriguez JJ, Gillies RJ, Stopeck AT. Diffusion MRI with semi-automated segmentation can serve as a restricted predictive biomarker of the therapeutic response of liver metastasis. *Magn Reson Imaging*. 2015 Dec;33(10):1267-73. doi: 10.1016/j.mri.2015.08.006. Epub 2015 Aug 15. PubMed PMID: 2628400. PubMed Central PMCID: 4658325.

123. Bea JW, Thomson CA, Wertheim BC, Nicholas JS, Ernst KC, Hu C, Jackson RD, Cauley JA, Lewis CE, Caan B, **Roe DJ**, Chen Z. Risk of mortality according to body mass index and body composition among postmenopausal women. *Am J Epidemiol* 2015 Oct 1;182(7):585-96. doi: 10.1093/aje/kwv103. [Epub ahead of print] PubMed PMID: 26350478.
124. LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttmann AM, Nagle RB, Abril ER, Farrell K, Hsu CH, **Roe DJ**, Gerner EW, Ignatenko NA, Barton JK. Time-serial assessment of drug combination interventions in a mouse model of colorectal carcinogenesis using optical coherence tomography. *Cancer Growth Metastasis*. 2015 Sep 7;8(Suppl 1):63-80. Doi: 10.4137/CGM.S21216. eCollection 2015. PubMed PMID: 26396545; PubMed Central PMCID: PMC4562605.
125. Hingle MD, Turner T, Kutob R, Merchant N, **Roe DJ**, Stump C, Going SB. The EPIC kids study: a randomized family-focused YMCA-based intervention to prevent type 2 diabetes in at-risk youth. *BMC Public Health*. 2015; 15:1253. Published online 2015 Dec 18. Doi: 10.1186/s12889-015-2595-3. PubMed Central PMCID: PMC4683710.
126. Chalasani P, Marron M, **Roe D**, Clarke K, Iannone M, Livingston RB, Shan JS, Stopeck AT. A Phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. *Cancer Med* 2015 Jul;4(7):1051-9. doi: 10.1002/cam4.447. Epub 2015 Mar 31. PubMed PMID: 25826750; PubMed Central PMCID: PMC4529343.
127. Patanwala AE, Erstad BL, **Roe DJ**, Sakles JC. Succinylcholine is associated with increased mortality when used for rapid sequence intubation of severely brain injured patients in the Emergency Department. *Pharmacotherapy* 2016;36(1):57-63. Doi: 10.1002/phar.1683. PubMed PMID: 26799349
128. Tate TH, Baggett B, Rice PF, Koevary JW, Orsinger GV, Nymer AC, Welge WA, Saboda K, **Roe DJ**, Hatch KD, Chambers SK, Utzinger U, Barton JK. Multispectral fluorescence imaging of human ovarian and fallopian tube tissue for early-stage cancer detection. *J Biomed Opt* 2016; May 1;21(5):56005. doi: 10.1117/1.JBO.21.5.056005. PubMed PMID: 27220626.
129. Jacobs ET, Haussler MR, Alberts DS, Kohler LN, Lance P, Martinez ME, **Roe DJ**, Jurutka PW. Association between circulating vitamin D metabolites and fecal bile acid concentrations. *Cancer Prev Res (Phila)*. 2016 May 2. pii: canprevres.0033.2016. [Epub ahead of print] PubMed PMID: 27138789. PubMed Central PMCID: PMC4993194
130. Kohler LN, Garcia DO, Harris RB, Oren E, **Roe DJ**, Jacobs, ET. Adherence to diet and physical activity cancer prevention guidelines and cancer outcomes: A systematic review. *Cancer Epidemiol Biomarkers Prev* 2016 July; 25:1018-28. doi: 10.1158/1055-9965.EPI-16-0121 Epub 2016 June 23. Review. PubMed PMID: 27340121. PubMed Central PMCID: PMC4940193

131. Thompson PA, Ashbeck EL, **Roe DJ**, Fales L, Buckmeier J, Wang F, Bhattacharyya S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez ME, Alberts DS, Lance P. Selenium supplementation for prevention of colorectal adenomas and risk of associated type 2 diabetes. *J Natl Cancer Inst.* 2016 Aug 16;108(12). Pii: djw152. Doi: 10.1093/jnci/djw152. Print 2016 Dec. PubMed PMID: 27530657.
132. Thompson PA, Ashbeck EL, **Roe DJ**, Fales L, Buckmeier J, Wang F, Bhattacharyya S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez ME, Alberts DS, Lance P. Celecoxib for the prevention of colorectal adenomas: results of a suspended randomized controlled trial. *J Natl Cancer Inst.* 2016 Aug 16;108(12). Pii: djw151. Doi: 10.1093/jnci/djw151. Print 2016 Dec. PubMed PMID: 27530656.
133. Larkey LK, **Roe DJ**, Smith L, Millstine D. Exploratory outcome assessment of Qigong/Tai Chi Easy on breast cancer survivors. *Compl Therapies Med* 2016; October 29: 196.
134. Chen Y, Gao M, Duncan JK, Ran D, **Roe DJ**, Belin MW, Wang M. Excisional keratectomy combined with focal cryotherapy and amniotic membrane inlay for recalcitrant filamentary fungal keratitis: A retrospective comparative clinical data analysis. *Experim & Therap Med* 2016; 12: 3014-3020. Doi: 10.3892/etm.2016.3699. PubMed PMID: 27882109. PubMed Central PMCID: PMC5103736
135. Lance P, Alberts DS, Thompson PA, Fales L, Wang F, San Jose J, Jacobs ET, Goodman PJ, Darke AK, Yee M, Minasian L, Thompson IM, **Roe DJ**. Colorectal adenomas in participants of the SELECT randomized trial of selenium and vitamin E for prostate cancer prevention. *Cancer Prev Res (Phila)* 2016 Oct 24. Pii: canprevres.0104. 2016 [Epub ahead of print] Doi: 10.1158/1940-6207.CSPR-16-0104. PubMed PMID: 27777235
136. Vasquez MM, Hu C, **Roe DJ**, Chen Z, Halonen M, Guerra S. Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application. *BMC Med Res Methodol* 2016 16(1):154. PubMed PMID: 27842498. PubMed Central PMCID:PMC 5109787
137. Langston M, Dennis L, Lynch C, **Roe D**, Brown H. Temporal trends in satellite-derived erythemal UVB and implications for ambient sun exposure assessment. *Int J Environ Res Public Health.* 2017 14:176. doi:10.3390/ijerph14020176. PubMed PMID: 28208641.
138. Kohler LN, Hibler EA, Harris RB, Oren E, **Roe DJ**, Jurutka PW, Jacobs ET. Greater adherence to cancer prevention guidelines is associated with higher circulating concentrations of vitamin D metabolites in a cross-sectional analysis of pooled participants from two chemoprevention trials. *J Nutr.* 2017 Mar; 147(3):421-429. Doio: 10.3945/jn.116.243352. Epub 2017 Jan 25. PubMed PMID: 28122932. PubMed Central PMCID:PMC5320404

139. Kim WS, Shin CN, Larkey LK, **Roe DJ**. Development and validation of the narrative quality assessment tool. *J Nurs Meas* 2017 Apr 1;25(1):171-183. Doi: 10.1891/1061-3749.25.1.171. PubMed PMID: 28395707.
140. Hassounah NB, Nunez M, Fordyce CA, **Roe DJ**, Nagle RB, Bunch TA, McDermott KM. Inhibition of ciliogenesis promotes hedgehog signaling, tumorigenesis, and metastasis in breast cancer. *Mol Cancer Res*. 2017 June 13, pii: molcanres.0034.2017. Doi: 10.1158/1541-7786. MCR-17-0034 [Epub ahead of print.] PubMed PMID: 28611083.
141. Thomson CA, Chow HHS, Wertheim BC, **Roe DJ**, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, Galons JP, Thompson PA. A randomized placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. *Breast Cancer Res Treat*. 2017 165:97-107. Doi: 10.1007/s10549-017-4292-7 [Epub ahead of print] PubMed PMID: 28560655. PubMed Central PMCID: PMC5571834.
142. Gordon JS, Armin J, Hingle MD, Giacobbi P, Cunningham, JK, Johnson T, Abbate K, Howe CL, **Roe DJ**. Development and evaluation of the see me smoke-free multi-behavioral mHealth app for women smokers. *Transl Behav Med*, 2017 7(2):172-184. Doi: 10.1007/s13142-017-0463-7. PubMed PMID: 28155107. PubMed Central PMCID: PMC5526811.
143. Vasquez MM, Hu C, **Roe DJ**, Halonen M, Guerra S. Measurement error correction in the least absolute shrinkage and selection operator model when validation data are available. *Stat Methods Med Res* 2017 Jan 1:962280217734241. doi: 10.1177/0962280217734241. [Epub ahead of print] PubMed PMID: 29166842
144. Bauman A, Ernst K, Hayden M, **Roe DJ**, Murray R, Agawo M, Munga S, Schmahl E, Taren D. Assessing community health: An innovative tool for measuring height and length. *J Trop Pediatr*. 2018 Apr 1; 64(2): 146-150. Doi: 10.1093/tropej/fmx046. PubMed PMID: 28673046. PubMed Central PMCID: PMC5916379.
145. Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, **Roe DJ**, Dong Z, Bode AM, Petricoin EF 3rd, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE. Pharmacological TLR4 antagonism using topical resatorvid blocks solar UV-induced skin tumorigenesis in SKH-1 mice. *Cancer Prev Res (Phil)*. 2018 May; 11(5): 265-278. doi: 10.1158/1940-6207.CAPR-17-0349. Epub 2018 Feb 1. PubMed PMID: 2943761. PubMed Central PMCID: PMC5932085.
146. Martinez JA, Yang J, Wertheim BC, **Roe DJ**, Schriewer A, Lance P, Alberts DS, Hammock BD, Thompson PA. Celecoxib use and circulating oxylipins in a colon polyp prevention trial. *PLoS ONE* 2018 Apr 26; 13(4):e0196398. doi: 10.1371/journal.pone.0196398. eCollection 2018. PubMed PMID: 29698447. PubMed Central PMCID: PMC5919576.

147. Laniewski P, Barnes D, Goulder A, Cui H, **Roe DJ**, Chase DM, Herbst-Kralovetz MM. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. *Sci Rep*. 2018 May 15;8(1):7593. doi: 10.1038/s41598-018-25879-7. PubMed PMID: 29765068. PubMed Central PMCID: PMC5954126.
148. Hetherington-Rauth M, Bea JW, Blew RM, Funk JL, Hingle MD, Lee VR, **Roe DJ**, Wheeler MD, Lohman TG, Going SB. Relative contributions of lean and fat mass to bone strength in young Hispanic and non-Hispanic girls. *Bone* 2018 May 22; 113-144. doi: 10.1016/j.bone.2018.05.023. [Epub ahead of print] PubMed PMID: 29800691.
149. Hetherington-Rauth M, Bea JW, Blew RM, Funk JL, Lee VR, Varadi TC, **Roe DJ**, Wheeler MD, Going SB. Effect of cardiometabolic risk factors on the relationship between adiposity and bone mass in girls. *Int J Obes (Lond)* 2018 June 11. Doi: 10.1038/s41366-018-0134-x. PubMed PMID: 29892038.
150. Gilligan AM, Alberts DS, **Roe DJ**, Skrepnek GH. Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer. *Am J Med* 2018 June 12. Pii: S0002-9343(18)30509-6. doi: 10.1016/j.amjmed.2018.05.020. [Epub ahead of print] PubMed PMID: 29906429.
151. Augustus GJ, **Roe DJ**, Jacobs ET, Lance P, Ellis NA. Is increased colorectal screening effective in preventing distant disease? *PLoS ONE* 2018 13(7):e0200462. doi: 10.1371/journal.pone.0200462. eCollection 2018. PubMed PMID: 30001362. PubMed Central PMCID: PMC6042755.
152. Padilla-Rodriguez M, Parker SS, Adams DG, Westerling T, Puleo JI, Watson AW, Hill SM, Noon M, Gaudin R, Aaron J, Tong D, **Roe DJ**, Knudsen B, Mouneimne G. The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. *Nat Commun* 2018 Jul 30;9(1):2980. doi:10.1038/s41467-018-05367-2. PubMed PMID: 30061623.
153. Kohler LN, Harris RB, Oren E, **Roe DJ**, Lance P, Jacobs ET. Adherence to nutrition and physical activity cancer prevention guidelines and development of colorectal adenoma. *Nutrients* 2018,10(8), 1098; <https://doi.org/10.3390/nu10081098>. PubMed PMID: 30115827.
154. Bui DP, Oren E, **Roe DJ**, Brown HE, Harris RB, Knight GM, Gilman RH, Grandjean L. A case control study to identify community venues associated with genetically clustered multidrug-resistant tuberculosis in Lima, Peru. *Clin Infect Dis* 2018 Sep 5. Doi: 10.1093/cid/ciy746. [Epub ahead of print]. PubMed PMID: 30239609.
155. Mandair D, Ho Q-A, Wertheim B, Johnson G, Roe D, Watchman C, Yi SK. Comparison of two thermoplastic immobilization mask systems in daily volumetric image guided radiation therapy for head and neck cancers. *Biom. Phys. Eng. Express* 2018 4 055007.

156. Bea JW, Funk J, Hetherington-Rauth M, Wertheim BC, Mosquiera L, Thuraisingam R, Lee V, Blew R, Lohman T, **Roe DJ**, Going S. Anthropometry versus imaging for prediction of inflammation among Hispanic girls. *Obesity*, 2018 26, 1594-1602. Doi:10.1002/oby.22265. PubMed PMID: 30277029. PubMed Central PMCID: PMC6171347.
157. Ding J, Stopeck AT, Gao Y, Marron MT, Wertheim BC, Altbach MI, Galons JP, **Roe DJ**, Wang F, Maskarinec G, Thomson CA, Thompson PA, Huang C. Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI. *J Magn Reson Imaging* 2018 Oct;48(4):971-981. doi: 10.1002/jmri.26041. Epub 2018 Apr 6. PubMed PMID: 29630755. PubMed Central PMCID: PMC6173993.
158. Huang S, Hu C, Bell ML, Billheimer D, Guerra S, **Roe D**, Vasquez MM, Bedrick EJ. Regularized continuous-time Markov Model via elastic net. *Biometrics* 2018 Sep;74(3):1045-1054. Doi: 10.1111/biom.12868. Epub 2018 Mar 13. PMID: 29534304.
159. Hetherington-Rauth M, Bea JW, Blew RM, Funk JL, Lee VR, **Roe DJ**, Sardinha LB, Going SB. Relationship of cardiometabolic risk biomarkers with DMA and pQCT bone health outcomes in young girls. *Bone*. 2018 Dec 18;12:4520458. Doi: 10.1016/j.bone.2018.12.013. [Epub ahead of print]. PubMed PMID: 30572143.
160. Nuño V, Wertheim BC, Murphy BS, Wahl RA, **Roe DJ**. Testing the efficacy of the Nurtured Heart Approach to reduce ADHD symptoms in children by training parents: Protocol for a randomized controller trial. *Contemp Clin Trials Commun*. 2019; 76.

Scholarly Presentations (2010 – Present)

Seminars

'Reading the Statistical Methods Literature.' Epidemiology/Biostatistics Seminar, January 2010.

'Measurement in Cancer Prevention and Control Clinical Trials.' Cancer Prevention and Control Seminar, September 2010.

'Measurement and Statistical Analysis Issues in Intervention Studies.' Mel and Enid Zuckerman College of Public Health Scholar Seminar, November 2010.

'Power for Tests of Interaction: Effect of Raising the Type I Error Rate.' Biostatistics Journal Club, March 2011.

'Matrixx v. Siracusano and Student v. Fisher: Statistical Significance on Trial.' Biostatistics Seminar, August 2011.

"On Judging the Significance of Differences by Examining the Overlap Between Confidence Intervals." Biostatistics Journal Club, January 2012.

"Statistics: An All-Encompassing Discipline", Biostatistics Journal Club, March 2012.

Grant and Contract Funding

Federal

Principal Investigator

July 2016 – June 2021	Biostatistics Shared Resource, Cancer Center Core Support Grant, NCI 2P30CA23074-36, Overall Principal Investigator: Andrew S. Kraft, M.D., Current year Biostatistics budget: \$233,997, 28% effort. Total Grant Award: \$2,301,904
July 2009 – June 2016	Biometry Shared Service, Cancer Center Core Support Grant, NCI 5P30 CA23074-31, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$1,176,320, Biometry Current year Budget: \$226,491, 25% effort
September 2008 – August 2013	Core D Biostatistics, SPORE in Lymphoma (Subagreement U of Rochester and U of Arizona), NCI 5P50 CA130805-02, Biometry Budget \$12,082, 2% effort.
July 2007 – June 2012	Biometry Core, Therapeutic Targeting of Hypoxic and Oxidative Stress; NCI P01 CA17094, Overall Principal Investigator: Robert Dorr, Ph.D., Biometry Budget: \$240,669; Biometry Current Year Budget: \$47,821; Program Project budget: \$6,559,769, 5% effort
August 2005 – November 2010	Biometry Core, Colon Cancer Prevention Program Project, NCI P01 CA41108, Overall Principal Investigator: Peter Lance, M.D., Biometry budget: \$579,095, Biometry Current Year Budget: \$116,092, 10% effort
February 2003 – January 2005	Shared Resources Core, Excellence in Partnership for Community Outreach, Research on Health Disparities and Training (EXPORT); NIMHHD P60 MD-000155-01, Overall Principal Investigator: G. Marie Swanson, Ph.D., M.P.H., Shared Resources Budget: \$522,711; Shared Resources Current Year Budget: \$138,321; Total Grant budget: \$6,000,000, 10% effort
November 2001 – December 2006	Biometry Core, Survival Signals for Molecular Target Assessment, NCI U54 CA 90821, Overall Principal Investigator: Garth Powis, D.Phil., Biometry budget: \$301,444; Biometry Current Year Budget: \$56,202; Program Project budget: \$8,296,948, 10% effort.

January 2001 – December 2005	Biometry Core, New Drug Targets for Apoptosis; NCI CA17094-23A, Overall Principal Investigator: Robert Dorr, Ph.D., Biometry Budget: \$386,754; Biometry Current Year Budget: \$72,847; Program Project budget: \$4,516,788, 10% effort.
January 2001 – December 2005	Biometry Core, Apoptosis in Colon Cancer Chemoprevention, NCI CA-72008-04A1, Overall Principal Investigator: Eugene W. Gerner, Ph.D., Biometry budget: \$536,606; Biometry Current Year Budget: \$152,435; Program Project budget: \$6,691,216, 10% effort
September 2000 – June 2003	Biometry Core, Colon Cancer Prevention Program Project, NCI CA41108, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$1,473,110, Biometry Current Year Budget: \$295,323 Program Project budget: \$12,912,890, 20% effort
August 1998 – February 2002	Biometry Shared Service, Cancer Center Core Support Grant, NCI CA23074, Overall Principal Investigator: Daniel Von Hoff, M.D., Biometry budget: \$1,436,495, Biometry Current year Budget: \$136,351; Core Support budget: \$6,755,179, 10% effort
July 1998 – June 2003	Biometry and Computing Core, Chemoprevention of Skin Cancer Program Project, NCI CA27502, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$1,123,277, Biometry Current year Budget: \$222,891; Program Project budget: \$9,239,674, 5% effort
July 1997 - June 2000	Biometry Core, Apoptosis in Colon Cancer Chemoprevention, NCI CA72008, Overall Principal Investigator: Eugene W. Gerner, Ph.D., Biometry budget: \$89,169, Program Project budget: \$1,551,550, 5% effort
July 1997 - February 2000	Biometry Core, Colon Cancer Prevention Program Project, NCI CA41108, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$827,722; Program Project budget: \$6,558,764, 20% effort
July 1997 - June 1998	Biometry Shared Service, Cancer Center Core Support Grant, NCI CA23074, Overall Principal Investigator: Sydney E. Salmon, M.D., Biometry budget: \$383,575, Core Support budget: \$6,039,893, 20% effort

July 1997 - November 1997	Biometry and Computing Core, Chemoprevention of Skin Cancer Program Project, NCI CA27502, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$301,488, Program Project budget: \$10,065,667, 10% effort
December 1993 - November 1998	Biometry and Computing Core, Medical Oncology Program Project, NCI CA17094, Overall Principal Investigator: Sydney E. Salmon, M.D., Biometry budget: \$1,305,453, Program Project budget: \$7,599,364, 50% effort
May 1992 - December 1993	Biometry Shared Resource, Cancer Center Core Support Grant, NCI CA23074, Overall Principal Investigator: Sydney E. Salmon, M.D., Biometry budget: \$383,575, Core Support budget: \$6,039,893, 20% effort
May 1992 - December 1993	Biometry Core, Colon Cancer Prevention Program Project, NCI CA41108, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$827,722, Program Project budget: \$6,558,764, 10% effort
May 1992 - December 1993	Biometry and Computing Core, Chemoprevention of Skin Cancer Program Project, NCI CA27502, Overall Principal Investigator: David S. Alberts, M.D., Biometry budget: \$301,488, Program Project budget: \$10,065,667, 5% effort
May 1992 -May 1993	Biometry Core, Cytogenetic Oncology Program Project, NCI CA41183, Overall Principal Investigator: Raymond Taetle, M.D., Biometry budget: \$361,600, Program Project budget: \$6,234,364, 15% effort
Co-Investigator	
September 2014 – May 2018	Arizona PRIDE-25: Advanced Health Disparities Training Program in Heart, Lung, Blood and Sleep Conditions. Skip Garcia, Ph.D. and Francisco Moreno, Ph.D., P.I.'s. \$4,668, 2% effort.
September 2013 – June 2018	Metformin for Reduction of Obesity-Associated Breast Cancer Risk. Sherry Chow, P.I. \$5,191, 5% effort.
January 2013 – December 2018	Obesity and Bone Development in Young Girls, NCI, Principal Investigator: Scott Going Ph.D., \$11,788, 5% effort.
January 2012 – December 2017	NSAID Effects on Clinical and Imaging Breast Biomarkers, NCI, Co-Principal Investigators: Alison Stopeck, M.D. and Patricia Thompson-Carino, Ph.D., \$12,961, 5% effort

August 2011 – July 2014	Selenium Colorectal Cancer Chemoprevention Trials, NCI 1R01 CA151708-01A1, Co-Principal Investigators: Peter Lance, M.D. and Patricia Thompson-Carino, Ph.D., \$25,921, 10% effort
January 2011 – December 2015	HomeStyles: Shaping Home Environments and Lifestyle Practices to Prevent Childhood Obesity: A Randomized Controlled Trial, USDA AFRI Childhood Obesity Program, Principal Investigator: Nobuko (Kay) Hongu, Ph.D., \$7,770, 3% effort
July 2010 – June 2015	Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer Survivors, NCI 1R01 CA149417-01A1, Principal Investigator: Cynthia Thomson, Ph.D., \$14,378, 5% effort
April 2010 – March 2015	Vitamin D Status, Genetic Variation in Vitamin D Signaling and Metabolism, and Risk of Colorectal Adenoma, NCI 1R01 CA140285-01A1, Co-Principal Investigators: Elizabeth Jacobs, Ph.D. and Peter Jurutka, PhD., \$4,517, 2% effort
September 2009 – September 2014	Southwest Center for Community Health Promotion, CDC U48-DP000041, Principal Investigator: Scott Carvajal, Ph.D., \$5,282, 2% effort
January 2009 – December 2012	Stealth Health: Youth Innovation, Mobile Technology, Online Social Networking, USDA 2009-55215-05187 Principal Investigator: Scott Going, Ph.D., \$10,016, 4% effort
June 2008 – May 2011	Serum 25 (OH)D, Vitamin D Intake, and Breast Cancer Recurrence in the WHEL Study, NCI 1R01 CA310520, Principal Investigator: Elizabeth Jacobs, Ph.D., \$52,603, 2% effort
September 2007 – July 2012	Colorectal Neoplasia in SELECT Participants, NCI 1R01 CA124862-01A1, Principal Investigator: Peter Lance, M.D., \$7,837, 3.5% effort
February 2007 – January 2012	Storytelling for Colorectal Health among Latinos, NCI R01 CA118663, Principal Investigator: Linda Larkey, Ph.D., \$14,792, 4% effort
October 2006 – September 2009	Qigong Effects on Fatigue and Cognitive Function after Treatment for Breast Cancer, NCCAM R21 AT002706, Principal Investigator: Linda Larkey, Ph.D., \$125,000, 4% effort

July 2006 – June 2011	Diffusion MRI as Biomarker for Therapy Response in Breast Cancer Metastases, NCI R01 CA119046, Principal Investigator: Alison Stopeck, M.D., \$18,942, 10% effort
July 2006 – May 2010	Storytelling to Promote Colorectal Screening in Primary Care Clinics, NCI R01 CA116467, Principal Investigator: Linda Larkey, Ph.D., \$567,531, 7% effort
September 2004 – September 2009	Southwest Center for Community Health Promotion, CDC U48-DP000041, Principal Investigator: Lisa Staten, Ph.D., \$732,657, 15% effort
November 2003 – October 2004	Partnership in Public Health - Arizona Academic Health Department, Association of Schools of Public Health, Principal Investigators: G. Marie Swanson, Ph.D., M.P.H. and Catherine R. Eden, Ph.D., Budget: \$100,000, 2% effort
July 2003 – June 2004	Biometry Core, Colon Cancer Prevention Program Project, NCI CA41108, Principal Investigator: David S. Alberts, M.D., Biometry budget: \$1,473,110, Biometry Current Year Budget: \$295,323 Program Project budget: \$12,912,890, 5% effort
February 2002 – June 2003	Biometry Shared Service, Cancer Center Core Support Grant, NCI CA23074, Principal Investigator: Daniel Von Hoff, M.D., Biometry budget: \$1,436,495, Biometry Current year Budget: \$136,351; Core Support budget: \$6,755,179, 10% effort
September 2000 – April 2001	Cancer Drugs Active Against Signal Transduction Targets, NCI CA52995-12, Principal Investigator: Garth Powis, D.Phil., 3% effort
April 2000 – March 2003	Antioxidant Nutrients Among a Brazilian Population, NCI R01 CA81310, Principal Investigator: Anna Giuliano, Ph.D., 5% effort
September 1999 – September 2001	Telomere and Telomerase Interactive Agents, NCI CA67760, Principal Investigator: Daniel Von Hoff, M.D., 3% effort
July 1999 – June 2001	Polymorphism & HPV Persistence, NCI CA23074, Principal Investigator: Paula Inserra, M.D., 5% effort (no salary)

August 1998 – July 1999	Fruit & Vegetable Intake & Effects in Smokers, NCI CA73329, Principal Investigator: Yei Mei Peng, Ph.D., 4% effort
September 1994 - August 1997	Development of Biomarkers for Prevention Clinical Trials, NCI CA63821, Principal Investigator: Yei-Mei Peng, Ph.D., \$568,530, 5% effort
July 1994 - June 1996	Biomarkers for Assessing Antioxidant Chemopreventives, NCI CA62946, Principal Investigator: Yeh-Shan Peng, Ph.D., \$75,750, 3% effort.
June 1993 - May 1995	Biometry Core, Cytogenetic Oncology Program Project, NCI CA41183, Principal Investigator: Raymond Taetle, M.D., Biometry budget: \$361,600, Program Project budget: \$6,234,364, 10% effort

State of Arizona

Co-Investigator

July 2000 – June 2002	Effects of Antioxident Nutrients and Smoking on Type Specific HPV, Arizona Disease Control Research Commission 10004, Principal Investigator: Anna Giuliano, PhD, \$436,357, 10% effort (no salary)
July 1999 – June 2001	Novel Anticancer Drug Discovery and Development, Arizona Disease Control Research Commission 20009, Principal Investigator: Garth Powis, D.Phil., 5% effort
July 1996 - June 1999	Effects of Smoking on Persistent HPV Infection Among Reproductive Age Women, Arizona Disease Control Research Commission, Principal Investigator: Anna Guiliano, Ph.D., \$379,673, 5% effort (no salary)
July 1988 - June 1990	Comprehensive Data Collection and Statistical Analysis of HIV Infected Patients in Arizona, Arizona Disease Control Research Commission, Principal Investigator: Eskild Petersen, M.D., \$49,108, 10% effort.

Industry

Principal Investigator

March 1996 - October 1996	Statistical Analysis of Membership Survey, Southwest Oncology Group, \$7,000, 5% effort
August 1992 - July 1993	Statistical Analysis of 1993 Membership Survey, American Society of Clinical Oncology, \$24,000, 10% effort

Co-Investigator

January 2001 – December 2001 Actigall (Phase III) Center #1, Novartis, Principal
Investigator: David Alberts, MD, 5% effort

This is a true and accurate statement of my activities and accomplishments. I understand that misrepresentation in securing promotion and tenure may lead to dismissal or suspension under ABOR Policy 6-201 J.1.b.